Aarti Pharmalabs Limited reported a 65.4% year-on-year surge in consolidated net profit to ₹761 crore for the first quarter of FY27 (Q1FY27), driven by robust demand in its Xanthine derivatives and Contract Development and Manufacturing Organization (CDMO) segments. Consolidated operational revenue climbed 38.7% to ₹5,358 crore, while EBITDA margins expanded by 10 basis points quarter-on-quarter to 24.75%, reflecting improved operational efficiency despite elevated raw material prices. The strong profitability turnaround was further supported by a gain from foreign exchange movements and a higher share of profit from its joint venture, Ganesh Polychem Limited.

The filing, submitted under Regulation 30 of the SEBI (LODR) Regulations 2015 on August 10, 2026, details the company’s financial performance alongside strategic capacity expansions. Aarti Pharmalabs highlighted that geopolitical tensions have kept raw material prices at elevated levels, though early indications of supply chain easing are emerging. Notably, production at the Unit 4 Steroid API Block was temporarily impacted by a six-week debottlenecking shutdown, which successfully unlocked a one-third capacity increase. The company also disclosed that fair value movements on long-dated USD forward contracts under FVTPL impacted reported profitability, with previous quarterly figures restated accordingly.

Financial Performance Highlights

The company’s consolidated results show significant improvement across key metrics compared to the same period last year. Standalone net profit rose 49.2% year-on-year to ₹713 crore. The following table outlines the key financial figures for Q1FY27:

Standalone operational revenue grew 42.4% to ₹5,346 crore, with standalone EBITDA rising 39.5% to ₹1,327 crore. The net debt-to-equity ratio stood at 0.32x as of FY26, indicating a conservative leverage position amidst aggressive capex plans.

Segmental Growth and Strategic Outlook

Xanthine derivatives remained the largest revenue contributor, accounting for 57% of total revenue in Q1FY27, followed by APIs and intermediates at 30%. The CDMO segment, while contributing 7% of revenue, showed strong momentum with sales reaching ₹276 crore in FY26, up from ₹32 crore in FY22. Management projects CDMO sales to grow by 40-50% in FY27, targeting approximately ₹380 crore.

Geographically, international sales constituted 60% of total revenue, with the Xanthine segment seeing 79% of its sales internationally. This diversification supports the company’s “China+1” strategy, positioning it as a non-Chinese dependent manufacturer with the world’s third-largest Xanthine derivatives capacity.

What the Numbers Show

A critical observation from the filing is the divergence between revenue growth and margin expansion. While operational revenue increased by nearly 39%, EBITDA margins expanded modestly, suggesting that input cost pressures are being partially offset by pricing power and mix shift towards higher-margin CDMO products. Furthermore, the inclusion of Ganesh Polychem Limited as a joint venture from April 1, 2025, has altered the comparability of consolidated figures, with the equity method of accounting now applying. This structural change contributed ₹74 crore to the pre-tax profit in Q1FY27, up from a loss of ₹18 crore in the same period last year, highlighting the growing significance of this partnership in the company’s bottom line.

Looking ahead, Aarti Pharmalabs announced an estimated investment of ₹149 crore for Atali Block 2, a brownfield capex project dedicated to CDMO/CMO activities. Commercialization is targeted for the second half of FY28. The company also initiated R&D investments in TIDES (Peptides & Oligonucleotides) to expand its portfolio capabilities, aiming for a 15-18% revenue and EBITDA CAGR over the next three to four years.

Aarti Pharma Labs reported a significant turnaround in its consolidated financial performance for the quarter ended June 30, 2026, driven by a sharp rise in operational income. The company’s consolidated income from operations jumped 117.5% year-on-year to ₹2,441.41 lakh, up from ₹1,122.50 lakh in Q1FY25. This growth helped narrow the consolidated net loss to ₹27.87 lakh from ₹1,156.89 lakh in the corresponding period last year. However, standalone operations remained under pressure, reporting a net loss of ₹33.56 lakh compared to a net profit of ₹58.65 lakh in Q1FY25.

The Board of Directors, at a meeting held on August 07, 2026, approved the unaudited financial results after review by the Audit Committee. The Statutory Auditors conducted a limited review of the results. The company filed the results with the stock exchanges under Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were subsequently published in Financial Express (English) and Loksatta – Jansatta (Gujarati) on August 09, 2026, as required under Regulation 47.

Financial Performance Highlights

Standalone total income from operations declined 25.1% quarter-on-quarter to ₹115.34 lakh from ₹154.12 lakh in Q4FY25. On a year-on-year basis, standalone income fell slightly by 2.4% to ₹115.34 lakh from ₹118.17 lakh in Q1FY25. The standalone segment reported a net loss before tax of ₹33.56 lakh, contrasting with a net profit before tax of ₹374.95 lakh in the preceding quarter.

In contrast, the consolidated segment showed robust momentum. Consolidated income from operations more than doubled compared to the previous year, rising from ₹1,122.50 lakh to ₹2,441.41 lakh. This operational surge significantly reduced the pre-tax loss to ₹45.65 lakh from ₹1,115.34 lakh in Q1FY25. The post-tax consolidated loss narrowed to ₹27.87 lakh, a substantial improvement from the ₹1,156.89 lakh loss recorded a year ago.

What the Numbers Show

The divergence between standalone and consolidated results highlights the contribution of subsidiaries or associates to the group’s overall performance. While Aarti Pharma Labs’ standalone core operations faced margin pressure—evidenced by the shift from a quarterly profit to a loss—the consolidated entity benefited from strong top-line growth across its group companies. The 117.5% year-on-year jump in consolidated income suggests that non-standalone entities are driving the current revenue expansion, offsetting the weaker standalone performance. Investors should monitor whether this consolidated growth trend sustains in subsequent quarters despite the standalone headwinds.